Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease

International Review of Neurobiology

Volumn 95, Issue C, 2010, Pages 207-225

  Kaakkola, Seppo ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

COMT inhibitor; Entacapone; Levodopa; Nebicapone; Parkinson's disease; Tolcapone

Indexed keywords

BENSERAZIDE; CARBIDOPA; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPA DECARBOXYLASE INHIBITOR; ENTACAPONE; LEVODOPA; METHYLTRANSFERASE INHIBITOR; NEBICAPONE; PLACEBO; RASAGILINE; TOLCAPONE; UNCLASSIFIED DRUG;

ANOREXIA; AREA UNDER THE CURVE; BOOK; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DEPRESSION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; ENZYME INHIBITION; EXCESSIVE DREAMING; HALLUCINATION; HEADACHE; HUMAN; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; MUSCLE CRAMP; NAUSEA; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

EID: 78649384409     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-381326-8.00009-0     Document Type: Chapter

References (71)

1. Ahtila S., Kaakkola S., Gordin A., Korpela K., Heinävaara S., Karlsson M., Wikberg T., Tuomainen P., Männist P.T. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers. Clin. Neuropharmacol. 1995, 18:46-57.
2. Almeida L., Soares-da-Silva P. Pharmacokinetics and pharmacodynamics of BIA 3-202, a novel COMT inhibitor, during first administration to humans. Drugs R D 2003, 4:207-217.
3. Almeida L., Vaz-da-Silva M., Silveira P., Falcao A., Maia J., Loureiro A., Torrao L., Machado R., Wright L., Soares-da-Silva P. Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/carbidopa. Clin. Neuropharmacol. 2004, 27:17-24.
4. Apud J.A., Mattay V., Chen J., Kolachana B.S., Callicott J.H., Rasetti R., Alce G., Iudicello J.E., Akbar N., Egan M.F., Goldberg T.E., Weinberger D.R. Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacology 2007, 32:1011-1020.
5. Baas H., Zehrden F., Selzer R., Kohnen R., Loetsch J., Harder S. Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease. Clin. Pharmacokinet. 2001, 40:383-393.
6. Bonifácio M.J., Palma P.N., Almeida L., Soares-da-Silva P. Catechol-O-methyltransferase and its inhibitors in Parkinson's disease. CNS Drug Rev. 2007, 13:352-379.
7. Brooks D.J. Safety and tolerability of COMT inhibitors. Neurology 2004, 62:S39-S46.
8. Cedarbaum J.M. Clinical pharmacokinetics of anti-Parkinsonian drugs. Clin. Pharmacokinet. 1987, 13:141-178.
9. Ceravolo R., Piccini P., Bailey D.L., Jorga K.M., Bryson H., Brooks D.J. 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease. Synapse 2002, 43:201-207.
10. Contin M., Martinelli P., Scaglione C., Avoni P., Albani F., Riva R., Baruzzi A. The effect of entacapone on levodopa rate of absorption and latency to motor response in patients with Parkinson disease. Clin. Neuropharmacol. 2008, 31:267-271.
11. Craddock N., Owen M.J., O'Donovan M.C. The catechol-O-methyl transferase (COMT) gene as a candidate for psychiatric phenotypes: evidence and lessons. Mol. Psychiatry. 2006, 11:446-458.
12. Creveling C.R. The role of catechol-O-methyltransferase in the inactivation of catecholestrogen. Cell Mol. Neurobiol. 2003, 23:289-291.
13. Da Prada M., Kettler R., Zurcher G., Schaffner R., Haefely W.E. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers. Eur. Neurol. 1987, 27(Suppl. 1):9-20.
14. Davis T.L., Roznoski M., Burns R.S. Acute effects of COMT inhibition on L-DOPA pharmacokinetics in patients treated with carbidopa and selegiline. Clin. Neuropharmacol. 1995, 18:333-337.
15. Deane K.H., Spieker S., Clarke C.E. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst. Rev. 2004, CD004554.
16. Deane K.H., Spieker S., Clarke C.E. Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst. Rev. 2004, CD004553.
17. Dingemanse J., Jorga K.M., Schmitt M., Gieschke R., Fotteler B., Zürcher G., Da Prada M., van Brummelen P. Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. Clin. Pharmacol. Ther. 1995, 57:508-517.
18. Dingemanse J., Jorga K., Zürcher G., Fotteler B., Sedek G., Nielsen T., van Brummelen P. Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects. Eur. J. Clin. Pharmacol. 1996, 50:47-55.
19. Dupont E., Burgunder J.M., Findley L.J., Olsson J.E., Dorflinger E. Tolcapone added to levodopa in stable parkinsonian patients: a double-blind placebo-controlled study. Tolcapone in Parkinson's Disease Study Group II (TIPS II). Mov. Disord. 1997, 12:928-934.
20. Factor S.A., Molho E.S., Feustel P.J., Brown D.L., Evans S.M. Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease. Clin. Neuropharmacol. 2001, 24:295-299.
21. Fava M., Rosenbaum J.F., Kolsky A.R., Alpert J.E., Nierenberg A.A., Spillmann M., Moore C., Renshaw P., Bottiglieri T., Moroz G., Magni G. Open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder. J. Clin. Psychopharmacol. 1999, 19:329-335.
22. Ferreira J.J., Almeida L., Cunha L., Ticmeanu M., Rosa M.M., Januario C., Mitu C.E., Coelho M., Correia-Guedes L., Morgadinho A., Nunes T., Wright L.C., Falcao A., Sampaio C., Soares-da-Silva P. Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease. Clin. Neuropharmacol. 2008, 31:2-18.
23. Ferreira J.J., Rascol O., Poewe W., Sampaio C., Rocha J.F., Nunes T., Almeida L., Soares-da-Silva P. A double-blind, randomized, placebo and active-controlled study of nebicapone for the treatment of motor fluctuations in Parkinson's disease. CNS Neurosci. Ther. 2010, Jul 23 [Epub ahead print].
24. Gordin A., Kaakkola S., Teräväinen H. Clinical advantages of COMT inhibition with entacapone - a review. J. Neural. Transm. 2004, 111:1343-1363.
25. Hauser R.A., Panisset M., Abbruzzese G., Mancione L., Dronamraju N., Kakarieka A. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. Mov. Disord. 2009, 24:541-550.
26. Heikkinen H., Saraheimo M., Antila S., Ottoila P., Pentikäinen P.J. Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope technique. Eur. J. Clin. Pharmacol. 2001, 56:821-826.
27. Jonkers N., Sarre S., Ebinger G., Michotte Y. Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylation in striatum of the rat. J. Neural. Transm. 2001, 108:559-570.
28. Jorga K.M., Fotteler B., Heizmann P., Zürcher G. Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy. Eur. J. Clin. Pharmacol. 1998, 54:443-447.
29. Jorga K.M., Larsen J.P., Beiske A., Schleimer M., Fotteler B., Schmitt M., Moe B. The effect of tolcapone on the pharmacokinetics of benserazide. Eur. J. Neurol. 1999, 6:211-219.
30. Jorga K.M., Sedek G., Fotteler B., Zürcher G., Nielsen T., Aitken J.W. Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly. Clin. Pharmacol. Ther. 1997, 62:300-310.
31. Kaakkola S. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs 2000, 59:1233-1250.
32. Kaakkola S., Teräväinen H., Ahtila S., Karlsson M., Naukkarinen T., Rita H., Gordin A. Entacapone in combination with standard or controlled-release levodopa/carbidopa: a clinical and pharmacokinetic study in patients with Parkinson's disease. Eur. J. Neurol. 1995, 2:341-347.
33. Kaakkola S., Tuomainen P., Wurtman R.J., Mannisto P.T. Effects of systemic carbidopa on dopamine synthesis in rat hypothalamus and striatum. J. Neural Transm. Park. Dis. Dement. Sect. 1992, 4:143-154.
34. Käenmäki M., Tammimäki A., Garcia-Horsman J.A., Myöhänen T., Schendzielorz N., Karayiorgou M., Gogos J.A., Männist P.T. Importance of membrane-bound catechol-O-methyltransferase in L-DOPA metabolism: a pharmacokinetic study in two types of Comt gene modified mice. Br. J. Pharmacol. 2009, 158:1884-1894.
35. Keating G.M., Lyseng-Williamson K.A. Tolcapone: a review of its use in the management of Parkinson's disease. CNS Drugs 2005, 19:165-184.
36. Keränen T., Gordin A., Harjola V.P., Karlsson M., Korpela K., Pentikäinen P.J., Rita H., Seppäl L., Wikberg T. The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin. Neuropharmacol. 1993, 16:145-156.
37. Keränen T., Gordin A., Karlsson M., Korpela K., Pentikäinen P.J., Rita H., Schultz E., Seppäl L., Wikberg T. Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. Eur. J. Clin. Pharmacol. 1994, 46:151-157.
38. Kiss L.E., Ferreira H.S., Torrao L., Bonifacio M.J., Palma P.N., Soares-da-Silva P., Learmonth D.A. Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase. J. Med. Chem. 2010, 53:3396-3411.
39. Koller W., Lees A., Doder M., Hely M. Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations. Mov. Disord. 2001, 16:858-866.
40. Kostrzewa R.M., Kostrzewa J.P., Brus R. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease. Amino Acids 2002, 23:57-63.
41. Kuoppamäki M., Korpela K., Marttila R., Kaasinen V., Hartikainen P., Lyytinen J., Kaakkola S., Hänninen J., Löyttyniemi E., Kailajärvi M., Ruokoniemi P., Ellmen J. Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily. Eur. J. Clin. Pharmacol. 2009, 65:443-455.
42. LeWitt P.A., Jennings D., Lyons K.E., Pahwa R., Rabinowicz A.L., Wang J., Guarnieri M., Hubble J.P., Murck H. Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. Mov. Disord. 2009, 24:1319-1324.
43. Lotta T., Vidgren J., Tilgmann C., Ulmanen I., Melen K., Julkunen I., Taskinen J. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 1995, 34:4202-4210.
44. Männist P.T., Kaakkola S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol. Rev. 1999, 51:593-628.
45. Myllylä V.V., Sotaniemi K.A., Illi A., Suominen K., Keränen T. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. Eur. J. Clin. Pharmacol. 1993, 45:419-423.
46. Nunes T., Machado R., Rocha J.F., Fernandes-Lopes C., Costa R., Torrao L., Loureiro A.I., Falcao A., Vaz-da-Silva M., Wright L., Almeida L., Soares-da-Silva P. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects. Clin. Ther. 2009, 31:2258-2271.
47. Nutt J.G., Fellman J.H. Pharmacokinetics of levodopa. Clin. Neuropharmacol. 1984, 7:35-49.
48. Nyholm D. Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease. Expert Rev. Neurother. 2006, 6:1403-1411.
49. Nyholm D. Pharmacokinetic optimisation in the treatment of Parkinson's disease: an update. Clin. Pharmacokinet. 2006, 45:109-136.
50. Nyholm D., Lennernäs H., Gomes-Trolin C., Aquilonius S.M. Levodopa pharmacokinetics and motor performance during activities of daily living in patients with Parkinson's disease on individual drug combinations. Clin. Neuropharmacol. 2002, 25:89-96.
51. Olanow C.W. Tolcapone and hepatotoxic effects. Tasmar Advisory Panel. Arch. Neurol. 2000, 57:263-267.
52. Olanow C.W., Watkins P.B. Tolcapone: an efficacy and safety review (2007). Clin. Neuropharmacol. 2007, 30:287-294.
53. Onofrj M., Thomas A., Iacono D., Di Iorio A., Bonanni L. Switch-over from tolcapone to entacapone in severe Parkinson's disease patients. Eur. Neurol. 2001, 46:11-16.
54. Rascol O., Brooks D.J., Melamed E., Oertel W., Poewe W., Stocchi F., Tolosa E. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005, 365:947-954.
55. Rautio J., Leppänen J., Lehtonen M., Laine K., Koskinen M., Pystynen J., Savolainen J., Sairanen M. Design, synthesis and in vitro/in vivo evaluation of orally bioavailable prodrugs of a catechol-O-methyltransferase inhibitor. Bioorg. Med. Chem. Lett. 2010, 20:2614-2616.
56. Rouru J., Gordin A., Huupponen R., Huhtala S., Savontaus E., Korpela K., Reinikainen K., Scheinin M. Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition. Eur. J. Clin. Pharmacol. 1999, 55:461-467.
57. Ruottinen H.M., Rinne U.K. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease. Clin. Neuropharmacol. 1996, 19:283-296.
58. Russ H., Muller T., Woitalla D., Rahbar A., Hahn J., Kuhn W. Detection of tolcapone in the cerebrospinal fluid of parkinsonian subjects. Naunyn Schmiedebergs Arch. Pharmacol. 1999, 360:719-720.
59. Sedek G., Jorga K., Schmitt M., Burns R.S., Leese P. Effect of tolcapone on plasma levodopa concentrations after coadministration with levodopa/carbidopa to healthy volunteers. Clin. Neuropharmacol. 1997, 20:531-541.
60. Seeberger L.C., Hauser R.A. Levodopa/carbidopa/entacapone in Parkinson's disease. Expert Rev. Neurother. 2009, 9:929-940.
61. Stocchi F., Rascol O., Kieburtz K., Poewe W., Jankovic J., Tolosa E., Barone P., Lang A.E., Olanow C.W. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann. Neurol. 2010, 68:18-27.
62. Suchowersky O., Bailey P., Pourcher E., Bulger L., Facciponte G. Comparison of two dosages of tolcapone added to levodopa in nonfluctuating patients with PD. Clin. Neuropharmacol. 2001, 24:214-220.
63. Tasmar P.I. Valeant Pharmaceuticals International. Tasmar® (tolcapone)tablets; prescribing information http://www.tasmar.com.
64. Tedroff J., Hartvig P., Bjurling P., Andersson Y., Antoni G., Langstrom B. Central action of benserazide after COMT inhibition demonstrated in vivo by PET. J. Neural Transm. Gen. Sect. 1991, 85:11-17.
65. Entacapone to tolcapone switch: multicenter double-blind, randomized, active-controlled trial in advanced Parkinson's disease. Mov. Disord. 2007, 22:14-19. The Entacapone to Tolcapone Switch Study Investigators.
66. Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients. Mov. Disord. 1999, 14:38-44. The Tolcapone Study Group.
67. Tiihonen J., Hallikainen T., Lachman H., Saito T., Volavka J., Kauhanen J., Salonen J.T., Ryynänen O.P., Koulu M., Karvonen M.K., Pohjalainen T., Syvälahti E., Hietala J. Association between the functional variant of the catechol-O-methyltransferase (COMT) gene and type 1 alcoholism. Mol. Psychiatry. 1999, 4:286-289.
68. Vieira-Coelho M.A., Soares-da-Silva P. Effects of tolcapone upon soluble and membrane-bound brain and liver catechol-O-methyltransferase. Brain Res. 1999, 821:69-78.
69. Waters C.H., Kurth M., Bailey P., Shulman L.M., LeWitt P., Dorflinger E., Deptula D., Pedder S. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group. Neurology 1997, 49:665-671.
70. Watkins P. COMT inhibitors and liver toxicity. Neurology 2000, 55:S51-52. discussion S53-S56.
71. Zhu B.T. Catechol-O-Methyltransferase (COMT)-mediated methylation metabolism of endogenous bioactive catechols and modulation by endobiotics and xenobiotics: importance in pathophysiology and pathogenesis. Curr. Drug Metab. 2002, 3:321-349.